Skip to main content
. Author manuscript; available in PMC: 2024 Jan 4.
Published in final edited form as: J Drug Issues. 2022 Aug 2;53(2):296–320. doi: 10.1177/00220426221109948

Table 4.

Regression Results for Courts Authorizing Different Types of MAT.

Outcome Predictor Level b Odds
Ratio
SE z p
Court offers buprenorphine n = 509 courts Intercept 1.80 0.45 4.03 <0.001
MAT substitutes one drug for another Court −0.77 0.46 0.16 −4.97 <0.001
Buprenorphine patient capacity/1k County 0.081 1.08 0.019 4.20 <0.001
Medicaid expansion State 0.70 2.01 0.27 2.62 <0.01
Court offers methadone n = 509 courts Intercept 0.85 0.42 2.01 0.045
Court type Court −0.051 0.95 0.26 −0.20 0.84
MAT substitutes one drug for another Court −0.61 0.54 0.14 −4.48 <0.001
Methadone providers/100k County 0.50 1.65 0.16 3.17 <0.01
Medicaid expansion State 1.05 2.86 0.29 3.62 <0.001
State mandates types of services State −0.55 0.58 0.26 −2.08 0.038
Court offers naltrexone n = 509 courts Intercept 1.38 0.56 2.45 0.014
Court type Court 0.60 1.83 0.30 2.00 0.045
MAT substitutes one drug for another Court −0.33 0.72 0.15 −2.15 0.031
Naltrexone providers/100k County 0.16 1.17 0.055 2.91 <0.01
Medicaid expansion State 0.50 1.65 0.39 1.28 0.20
State mandates types of services State −0.68 0.51 0.37 −1.84 0.066